Skip to main content
Toggle navigation
Drupal
Main navigation EN
About Crossject
Who we are
Governance
Partners
Our news
R&D
ZENEO® products
ZENEO®: needle-free technology
Pipeline
ZENEO® Sumatriptan
ZENEO® Adrenaline
ZENEO® Hydrocortisone
ZENEO® Midazolam
ZENEO® Naloxone
ZENEO® Methotrexate
ZENEO® Apomorphine
ZENEO® Terbutaline
Finances
Profile
Analyst coverage
Financial releases
Main navigation 2 EN
Press resources
Press releases
Image bank
Careers
Working at Crossject
Our careers
Available position and applications
Contact
FR
EN
Home
Finances
Financial releases
Financial releases
Release date
And
Year
All
2018
2017
2016
2015
2014
2013
Apply
2018/06/04
Business update may 2018
Read the release
2018/03/20
Annual 2017 results and business update
Read the release
2018/03/01
Financial calendar 2018
Read the release
2018/02/12
Free allotment of warrants to the shareholders and issue of a convertible bond
Read the release
2018/02/01
FDA grants orphan-drug designation to ZENEO® Midazolam
Read the release
2017/12/07
Business update
Read the release
2017/09/21
Interim 2017 results and business update
Read the release
2017/06/08
Business update Confirmation of the schedule of marketing authorisation filings
Read the release
2017/03/16
CROSSJECT receives €2.9M from Bpifrance as part of the PIAVE financing
Read the release
2017/03/06
CROSSJECT receives authorization to conduct Zeneo® Midazolam bioequivalence study
Read the release
Pagination
Current page
1
Page
2
Page
3
Next page
Next ›
Last page
Last »
